Novartis India Limited markets innovative prescription medicines across oncology, immunology, cardiovascular, and neuroscience therapies. The company leverages global research capabilities to introduce advanced treatments in India. Increasing demand for specialty medicines supports growth. Product innovation strengthens market leadership. Global healthcare expertise differentiates the business.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | Beta |
|---|---|---|---|---|---|---|---|
| ₹4,745 cr | — | — | 47.5 | 39.61 | 5.80 | 12.0% | — |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 575.95 ✓ Within 25% of the 52-week high · high 2,428.20 ✓ RS percentile 70 or more · RS 99 Trend template - the gate, measured: a modest 21-day edge. | 8/8 | Pass |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | — C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 2,428.20 ✓ S more volume on up days than down days (50 sessions) · 3.02x ✓ L RS percentile 80 or more · RS 99 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 3/4 | Average |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 2,588.80 ✗ Box bottom confirmed (3 sessions holding) · bottom 1,850.00 ✗ Close above the box top · close 1,921.60 ✗ Volume at least 1.5x its 50-day average · 0.1x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 34/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 2,588.80 ✗ Close above the prior 20-session high · 2,161.50 ✗ Close below the prior 20-session low · 1,850.00 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Graham | ✗ Price at or below the Graham number · Graham number 543.39 ✗ P/E 15 or less · P/E 48.5 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 5.80 — Current ratio 2 or more — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 28/100 | Expensive |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NOVARTIND this stock | -6.1 | +15.2 | +93.0 | +185.8 | +169.7 | +140.4 | 47.5 | 5.80 | 12.0 | — | — | — | — | 4,745 | — | — | 39.6 | — |
| PREMIERPOL | +30.2 | +43.3 | +103.1 | +140.8 | +275.1 | +641.0 | 30.1 | 6.69 | 24.1 | 32.9 | — | 0.00 | 24.3 | 1,123 | 396 | 37 | 3.5 | 0.61 |
| CALSOFT | -18.4 | +38.8 | +158.0 | +79.1 | +128.5 | -13.1 | 13.5 | 4.79 | 32.3 | 42.0 | — | 0.04 | — | — | 25 | 15 | 2.4 | 0.57 |
| VALIANTLAB | +14.2 | +119.9 | +111.8 | +70.1 | -27.6 | — | 47.7 | 2.46 | -1.2 | 0.8 | — | 0.14 | 88.7 | 764 | 306 | 16 | 3.0 | 0.81 |
| KENNAMET | -3.8 | +48.0 | +67.3 | +66.3 | +56.4 | +189.5 | 46.2 | 10.60 | 23.0 | — | — | — | — | 9,052 | — | — | 89.2 | — |
| AKSHARCHEM | +5.8 | +76.5 | +98.6 | +57.4 | +48.9 | -20.8 | 23.7 | 1.27 | -0.2 | 0.7 | — | 0.41 | 23.5 | 333 | 416 | 14 | 17.5 | 0.81 |
| CHEMBONDCH | -17.5 | -11.4 | +49.0 | +48.5 | — | — | 15.9 | 2.92 | 18.5 | — | — | 0.00 | 12.1 | 605 | 347 | 38 | 14.2 | 1.28 |
| IVP | -2.1 | +33.7 | +47.2 | +34.0 | +23.5 | +77.2 | 6.9 | 1.38 | 12.6 | 13.9 | — | 0.42 | 7.5 | 217 | 611 | 32 | 30.5 | 1.05 |
| MARALOVER | -2.2 | +5.6 | +29.1 | +29.1 | -15.4 | -28.2 | — | 2.17 | — | — | — | — | — | — | — | — | — | 1.03 |
| NAHARSPING | -7.2 | -11.0 | -1.6 | +25.4 | -11.3 | -47.6 | 11.4 | 0.60 | 1.5 | 3.2 | — | 0.65 | 11.0 | 901 | 3,365 | 76 | 21.9 | 1.22 |
| VHLTD | +22.1 | +17.3 | +9.5 | +21.2 | — | — | — | 3.89 | 7.2 | 7.1 | — | 0.99 | 29.1 | 1,042 | — | — | — | 0.19 |